MedChemExpress LLC’s Post

🌟 The mastermind behind gene regulation - the #transcriptional #condensate , whose assembly secrets remain to be unlocked 🔒. 📜 Recent research published in #Nature #Immunology has unveiled that the autoimmune regulator Aire orchestrates a multi-layered assembly mechanism, reshaping T-cell tolerance gene expression . The #Aire condensate assembles on enhancers, activating local transcription and bridging chromosomal breakpoints .Its enigma lies in the synergistic action of Aire's three domains: the caspase activation and recruitment domain (#CARD) for polymerization, the histone-binding domain (the first plant homeodomain PHD1), and the C-terminal tail (#CTT) 🔍. The study found that the delicate balance between PHD1 inhibition and CTT stimulation is crucial for the formation of transcriptionally active condensates , opening up a new perspective for precise regulation of transcriptional control! 🎉 https://lnkd.in/eGXeMFRS   For more push, please follow #Twitter: https://lnkd.in/gntQ9qE7   Related Product Recommendation:   #dCBP1 (https://lnkd.in/gm2_KFD);   #dBET6 (https://lnkd.in/edzpRjK);   #FITC (Fluorescein 5-isothiocyanate; https://lnkd.in/e5vuP_Cf);   #Doxycycline (https://lnkd.in/gumxT394);   #A485 (https://lnkd.in/gZzicvW3);   #DMSO (Dimethyl sulfoxide; https://lnkd.in/ephUV2dZ)   #NatImmunol #Transcriptional Condensates #Aire #Precise control #CARD #PHD1 #CTT #MCE #MedChemExpress

✨ #R162 is a Potent #GDH1/GLUD1 Inhibitor for Kinds of #Cancers Research 🎈 #Glutamate dehydrogenase 1 (#GLUD1) is a key #enzyme in the breakdown of #glutamine, which can convert glutamic acid into alpha ketoglutarate and enter the #TCA cycle.GLUD is activated by the direct binding of the essential amino acid leucine, thereby stimulating glutamic acid deamination and producing alpha KG. GLUD has two different #isoenzymes, GLUD1 and GLUD2, both of which are upregulated in human cancer, allowing cancer cells to utilize this pathway for growth and proliferation. #Knockdown of GDH1 significantly reduced the #cell #proliferation, colony formation, and #tumorigenesis ability of glioblastoma cells. GDH1 mediated glutamine breakdown is involved in #EGF promoted cell proliferation. Phosphorylated #ELK1 is enriched on the promoter of GDH1, thereby activating the transcription of GDH1 and promoting glutamine #metabolism. Here, we will introduce a potent GDH1/GLUD1 inhibitor for kinds of cancers research, #R162. 🔔 #R162 is a Potent GDH1/GLUD1 Inhibitor for Kinds of Cancers Research. Inhibition of GDH1 activity by R162 treatment results in decreased intracellular fumarate levels. It causes attenuated GPx activity, increased #ROS levels, and reduced cell proliferation in #H1299 and MDA-MB231 cells. This can be significantly rescued by methyl-α-KG treatment as well as by antioxidant NAC. R162 inhibits cell proliferation and #tumor growth potential of human cancer cells. In the second place, R162 does not result in a significant histopathological change between the vehicle-treated and R162-treated groups. R162 does not alter complete blood counts, or hematopoietic properties in #xenograft #tumor mouse #models. R162 results in significantly decreased tumor growth and masses in mice compared with control #mice. R162 effectively inhibits GDH1 activity in resected tumors from xenograft nude mice. All in all, R162 is a potent GDH1/GLUD1 inhibitor for kinds of cancers research. 👉 https://lnkd.in/gJkaPd3z 👉 For more detailed informations: https://lnkd.in/gGiigb-J

✨ #Cells #die in a variety of ways, including #apoptosis, #pyroptosis, #necrosis, and #ferroptosis......And, of course, #cuproptosis. So, how much do you know about cuproptosis?

✨ #XRD0394 is a potent and specific dual inhibitor of two #DNA damage response kinases, ATM and DNA-PKcs. This orally bioavailable molecule demonstrates significantly enhanced #tumor cell kill in the setting of therapeutic ionizing irradiation in #vitro and in #vivo. XRD-0394 also potentiates the effectiveness of topoisomerase I inhibitors in vitro. In #cells lacking BRCA1/2 XRD-0394 shows single-agent activity and synergy in combination with #PARP inhibitors. A phase Ia clinical trial (NCT05002140) with XRD-0394 in combination with radiotherapy has completed. 🎈 #MCE Raleted Products: https://lnkd.in/gn-Hmd69 👉 For more detailed information: https://lnkd.in/gAP9_JXq

🔔 The countdown to the MedChemExpress LLC #Webinar is ONE WEEK! We will welcome your participation! 😎 📢 Topic: #TGF-β #Signaling and #Organ #Fibrosis 🌟 Speaker: Joice Thomas Gavali 📆 Date: August 28, 2024 (Wednesday) 🕐 Time: 13:00 - 14:00 ET; 12:00 - 13:00 CT; 10:00 - 11:00 PT; 19:00 - 20:00 CEST ✅ Registration Link: https://lnkd.in/gFCaTvXF ✅ For More Information about the Webinar: https://lnkd.in/gEsnVcAf

✨ Comparison of multiple #cell #death modes. #Cuprotosis、 #Pyroptosis、#Ferroptosis、#Apoptosis

Breakthrough in #CRC Metabolism!🔥   A study published in Cancer Cell analyzed 1,251 samples, uncovering pivotal changes in plasma and fecal metabolites during CRC progression. Oleic acid exhibited pro-tumorigenic effects in CRC cells, patient-derived organoids, and two murine CRC models, while allocholic acid displayed opposing effects. They bind to α-enolase and FXR-1 in CRC cells respectively, modulating cancer pathways. Clinically validated, 17 plasma metabolites accurately diagnosed CRC with AUCs ranging from 0.848 to 0.987. 🔍   This research illuminates the characteristics, mechanistic significance, and diagnostic potential of plasma and fecal metabolomes in CRC! 🚀   https://lnkd.in/eGxkkspK   For more push, please follow #Twitter: https://lnkd.in/gntQ9qE7   Related Product Recommendation:   #AllocholicAcid (https://lnkd.in/eDyjwcUQ);   #ENOblock (AP-III-a4; https://lnkd.in/e6cBgP6R);   #CholicAcid (https://lnkd.in/gvvGQfrk);   #Dihydrothymine (5,6-Dihydro-5-methyluracil; https://lnkd.in/e3KCy4NE);   #LHistidine (https://lnkd.in/e9i7MFvw);   #OleicAcid (9-cis-Octadecenoic acid; 9Z-Octadecenoic acid; https://lnkd.in/emu-Aajp);   #GlyβMCA (https://lnkd.in/ehTrJ3SU)   #CancerCell #CRC #Metabolism #Plasma #FecalMetabolomes #MCE #MedChemExpress

✨ #GW0742 is a #PPARβ/δ Agonist for #Metabolic Disease Research 🎈 #PPARs (#Peroxisome proliferator-activated receptors) are ligand-activated transcription factors of nuclear #hormone #receptor superfamily comprising of the following three subtypes: #PPARα, #PPARγ, and #PPARβ/δ. PPARs play essential roles in the regulation of cellular differentiation, development, and #metabolism (carbohydrate, lipid, #protein), and #tumorigenesis of higher organisms. All PPARs heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the #DNA of target genes. Activation of PPAR-α reduces triglyceride level and is involved in regulation of energy homeostasis. Activation of PPAR-γ enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism. Among them, PPARβ/δ is expressed in many tissues, especially in brain, adipose tissue, and skin. 📣 #GW0742 (also called #GW610742) is a potent and high affinity PPARβ/δ agonist. GW0742 shows 1000-fold selectivity for PPAR β/δ over the other human subtypes. GW0742 is also a weak non-steroidal VDR antagonist. GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1ΔE9 astrocytes. GW0742 increases astrocytic expression of CPT1A. Similarly, in a mouse model of #Alzheimer's disease (#AD), the APP/PS1-mice, GW0742 (oral administration; 30 mg/kg) increases the expression of Cpt1a. GW0742 concomitantly reverses memory deficits in a fear conditioning test. GW0742 prevented Aβ-induced impairment of long-term potentiation in hippocampal slices. In Bleomycin instillation in mice, GW0742 (0.3 mg/kg; i.p.) reduces the lung injury and inflammation. GW0742 significantly inhibits #TNF-α and #IL-Iβ levels and significantly reduces the levels of #NFκB p65 in the lung. GW0742 decreases the #iNOS expression in Bleomycin instillation #mice. GW0742 reduces the #MAPK signalling pathway activation and the following damage to the lung triggered by #ERK cascade. 👉 https://lnkd.in/gbwjHtkZ 👉 For more detailed informations： https://lnkd.in/gp6V5NDB

✨ Published in #Molecular #Cell: Here, the article reports that #mice with conditional #knockout (cKO) #Ufl1, a UFMylation E3 ligase, in T cells exhibit effective #tumor control. Ufl1 cKO mice bearing tumors have a better response to anti-#CTLA-4 immunotherapy. Collectively, our findings uncover a crucial role of UFMylation in T cells and highlight UFL1 as a potential target for #cancer treatment. 🔔 Related Product Recommendation: #OVA #Peptide(257-264) TFA OVA Peptide(257-264) TFA is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I #MHC molecule, H-2Kb. https://lnkd.in/guwnnx6A 👉 For more detailed information: https://lnkd.in/gPFEBeuS

✨ #S130 is a Selective #ATG4B Inhibitor for Various #Cancers Research #ATG4B is a cysteine #protease that activates #LC3 for lipidation and recent studies suggest that it may be another promising target to inhibit #autophagy upstream of the #lysosome. Consistent with this idea, several #ATG4B inhibitors have been developed including #FMK9a, #NSC185058, and #S130. S130 have demonstrated significant in #vivo activity against #colon #tumor. Today, We will introduce S130. 🎈 S130 is a ATG4B inhibitor that inhibits autophagy #S130 is a high affinity, selective inhibitor of ATG4B (a major cysteine #protease) with an #IC50 of 3.24 µM. It suppresses autophagy flux. S130 suppresses autophagy and activates apoptosis by inhibiting ATG4B, leads to enhanced cytotoxicity. S130 (10 μM; 6 h) suppresses autophagy at the early LC3 priming step or late #autolysosome degradation stage. S130 accumulates autolysosomes with more lipidated LC3. S130 (0-25 μM; 48 h) induces cell death through inhibiting the activity of ATG4B at a dose higher than 6.3 µM. And such cytotoxicity might not cause cell death through #necroptosis. Nutrient deprivation enhances S130-induced cytotoxicity. It (0-10μM; 24 hours) suppresses approximately 79% of the cleavage of full-length LC3-GST at the 10 µM, while no substrates were processed in ATG4B KO cells. S130 displays obvious inhibitory effects on ATG4B. S130 (20 mg/kg; i.p.; daily; 3 weeks) suppresses #tumor growth, and shows an efficient in vivo #antitumor effect with a sound safety on vital organs. All in all, S130 is a selective ATG4B inhibitor for #cancers research. 👉 https://lnkd.in/gwQwmZNN 👉 For more detailed information: https://lnkd.in/gTQzVzZx